Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high193.00 04/01/18
52 week low43.45 18/08/17
52 week change 113.50 (241.49%)
4 week volume16,237,435 28/12/17

Latest NewsMore

ImmuPharma completes dosing in Lupuzor study

ImmuPharma has confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, p...

Grant of Options

RNS Number: 0005A Immupharma PLC 21 December 2017 21 DECEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Grant of Options ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 900,000 ordinary s...

Last patient completes dosing in LupuzorT Trial

RNS Number: 0003A Immupharma PLC 21 December 2017 21 DECEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Last patient completes dosing in Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the last patient has completed dosing within the...

Broker Forecast - finnCap issues a broker note on ImmuPharma PLC

finnCap today initiates coverage of ImmuPharma PLC (LON:IMM) with a buy investment rating and price target of 237p...

Holding(s) in Company

RNS Number: 7454X Immupharma PLC 28 November 2017 28 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Holding(s) in Company ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, has received notification from Alto Invest ("Alto") that Alto now holds 5,242,536 ordinary shares of 10p each in the...

Grant of Options

RNS Number: 4907X Immupharma PLC 24 November 2017 24 NOVEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Grant of Options ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 7,875,000 ordinar...

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

Fundamental DataMore

EPS-4.54
Dividend yield0 %

Latest discussion posts More

  • Upbeat Interview with Tim McCarthy CEO

    https://www.youtube.com/watch?v=zrmthFUsvoY
    18-Jan-2018
    Volsung
  • up oday

    thankx when will be Q1 results it is yo yo today 160-170 imho
    18-Jan-2018
    tikky
  • Re: up today

    RNS out today but they have the wrong date on it so click on the latest and you will see it.
    18-Jan-2018
    j-n-p

Users' HoldingsMore

Users who hold Immupharma also hold..

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account